赵文岭, 王兵. 替罗非班治疗急性冠状动脉综合征的安全性和有效性评价[J]. 蚌埠医学院学报, 2012, 36(9): 1059-1061.
    引用本文: 赵文岭, 王兵. 替罗非班治疗急性冠状动脉综合征的安全性和有效性评价[J]. 蚌埠医学院学报, 2012, 36(9): 1059-1061.
    ZHAO Wen-ling, WANG Bing. Comment on the safety and effectiveness of tirofiban in acute coronary syndrome[J]. Journal of Bengbu Medical College, 2012, 36(9): 1059-1061.
    Citation: ZHAO Wen-ling, WANG Bing. Comment on the safety and effectiveness of tirofiban in acute coronary syndrome[J]. Journal of Bengbu Medical College, 2012, 36(9): 1059-1061.

    替罗非班治疗急性冠状动脉综合征的安全性和有效性评价

    Comment on the safety and effectiveness of tirofiban in acute coronary syndrome

    • 摘要: 目的:探讨替罗非班治疗急性冠状动脉综合征(ACS)的安全性和有效性。方法:80例ACS患者分为观察组和对照组,每组40例,对照组采用常规治疗,观察组在对照组的基础上采用替罗非班治疗,比较2组患者治疗24 h时的肌钙蛋白T(cTnT)峰值水平,30 d时主要心脏不良事件的情况、心电图ST段回落率、左心室射血分数、不良反应及出血情况。结果:2组均未出现大出血和少量出血、血小板减少,观察组皮肤、黏膜出血发生率20.0%,与对照组的17.5%差异无统计学意义(P0.05);观察组在24 h时的cTnT峰值水平为(1.470.58)g/L,低于对照组的(2.340.49)g/L(P0.05)。观察组30 d时主要心脏不良事件的发生率2.5%,与对照组的12.5%差异无统计学意义(P0.05);观察组心电图ST段回落率80.0%,左心室射血分数(57.86.7)%,均优于对照组的60.0%、(45.44.8)%(P0.05)。结论:在常规治疗的基础上采用替罗非班治疗ACS能够减少心肌细胞损伤,改善心功能,主要心脏不良事件的发生有下降趋势,且安全性较好。

       

      Abstract: Objective: To explore the safety and effectiveness of tirofiban in treatment of acute coronary syndrome(ACS) .Methods: Eighty patients with ACS were divided into observation group and control group(40 cases each group) .The routine treatments were performed for the patients in control group,while tirofiban was administered additionally to the patients in observation group.Cardiac troponin T(cTnT) peak level in 24 hour was compared,major adverse cardiac events in 30d, rate of fall of ST segment, left ventricular ejection fraction, adverse reactions and bleeding condition were observed in two groups.Results: There was no bleeding even slight bleeding or thrombocytopenia in either case, and there was no difference of the occurrence rate of bleeding in skin and mucosa between the observation group and control group(20.0% vs.17.5%) (P0.05) .The cTnT peak level in 24 hours in observation group was obviously lower than that in control group,(1.47 0.58) g /L vs.(2.34 0.49) g /L(P0.05) .There was no difference about the occurrence rates of major adverse cardiac events in 30d in both groups(2.5% vs.12.5%) (P0.05) .The rate of fall of ST segment (80.0%) and left ventricular ejection fraction(57.8 6.7) % in observation group were significantly better than those in control group, 60.0% and (45.4 4.8 ) %,(P0.05 ) .Conclusions: For ACS patients, tirofiban based on the routine treatment can effectively decrease the incidence of myocardial cell injury, and it can improve cardiac function.There is a tendency that tirofiban can also decrease the major adverse cardiac events.Besides, its safety is better.

       

    /

    返回文章
    返回